 -- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results from Uncovering Rare Obesity testing program suggest up to 64.5 percent of individuals with early-onset, severe obesity may carry variants linked to rare genetic diseases of obesity -- -- Additional posters include encore presentations of data from Phase 3 trial evaluating setmelanotide in BBS and Phase 2 trial in HET obesity, as well as Phase 1b trial evaluating once-weekly setmelanotide -- BOSTON, Oct. 14, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today presented the first-ever data on the health related quality of life HRQOL and experience of patients with obesity due to POMC or LEPR deficiency and updated results from the Uncovering Rare Obesity URO genetic testing program at the Obesity Medicine Associations Overcoming Obesity 2021 Conference and its Digital Experience DX Oct. 14-23. 